MK-677 (Ibutamoren): Benefits, Dosage, Side Effects, and How to Get It
Medically reviewed by the Rite Aid Health Team · Last updated June 16, 2026
MK-677, also called ibutamoren, is an oral growth-hormone secretagogue and ghrelin-receptor agonist. It raises growth hormone and IGF-1, increases appetite, and is used for body composition, recovery, and sleep.
One thing to state plainly up front: MK-677 is not technically a peptide — it is a non-peptide small molecule.
It isn't a peptide — it's a non-peptide compound — but it works on the same growth-hormone axis as the secretagogue peptides and is commonly used alongside them. See our peptide therapy guide for the peptides it sits next to. Its defining practical feature is that it's taken orally, with no injection.
Almost done
Confirm your email to secure 20% off your first compounded-peptide order. We'll notify you when consultations and ordering open.
Get 20% off your first compounded-peptide order
Join the early-access waitlist and we'll notify you the moment consultations and ordering open.
What is MK-677?
MK-677 (ibutamoren) is a synthetic small molecule that mimics the action of ghrelin, the hormone that stimulates hunger and growth-hormone release. It is a non-peptide compound — unlike the GHRH analogs and secretagogue peptides on the rest of this site, it is not built from amino acids.
It produces a peptide-like effect on the growth-hormone axis through a different chemical class, which is why it sits alongside peptides in searches and stacks even though it is structurally distinct.
Is MK-677 a peptide?
No. MK-677 is a non-peptide growth-hormone secretagogue. It is a small organic molecule, not a chain of amino acids. People group it with peptides like ipamorelin and sermorelin because it acts on the same growth-hormone pathway and is used for the same goals, but the chemistry is different.
This distinction also matters for its regulatory status: MK-677 is not on the 2026 peptide reclassification list, because that list covers peptides.
Benefits and uses
What MK-677 is used for, by raising GH and IGF-1:
- Body composition. Sustained elevation of GH and IGF-1 is used to support lean mass and fat metabolism.
- Appetite increase. Because it acts on the ghrelin receptor, MK-677 reliably increases appetite — useful for those trying to gain, a drawback for those cutting.
- Sleep. Users report deeper sleep, consistent with GH's role in slow-wave sleep.
- Recovery. Elevated GH and IGF-1 support soft-tissue repair.
The oral route is the practical draw — it produces GH-axis effects without subcutaneous injection.
How it works
MK-677 binds the ghrelin receptor (the growth-hormone secretagogue receptor) in the pituitary and hypothalamus, mimicking ghrelin's signal to release growth hormone. The released GH raises IGF-1, and the ghrelin-receptor activity also drives the appetite increase.
Because it's orally bioavailable and long-acting, a single daily dose maintains elevated GH and IGF-1 around the clock — a different pattern from the short pulses produced by injectable secretagogues.
Dosage and administration
MK-677 is taken orally, typically once daily, which is its main point of difference from injectable GH peptides. Commonly cited ranges run in the milligram-per-day region, often taken at night to align with sleep.
These are not official dosing guidelines — MK-677 is a research chemical, not an FDA-approved product — and any use should be supervised by a provider.
If you are stacking it with injectable peptides, the peptide dosage calculator covers the injectable side of the protocol.
Side effects and safety
MK-677's side effects follow from sustained GH elevation and ghrelin-receptor activity, and they warrant active monitoring:
- Water retention. Common, from elevated GH.
- Increased appetite. Expected, and can be unwanted on a cut.
- Raised blood sugar. GH reduces insulin sensitivity, so fasting glucose and HbA1c can rise — the most important safety item to track.
- Lethargy or fatigue in some users.
MK-677 is a research chemical and not FDA-approved for human use. Because of the blood-sugar effect in particular, anyone using it should monitor glucose and metabolic markers and work with a provider.
Legal status and how to get MK-677
MK-677 is a research chemical, not an FDA-approved medication, and it is not on the April 2026 list of 12 peptides removed from the Section 503A Category 2 restriction — that list covers peptides, and MK-677 is a non-peptide compound.
It is also not on the agenda for the July 23–24, 2026 Pharmacy Compounding Advisory Committee meeting. Products sold online "for research use only" are not manufactured or quality-controlled for human use, and buying them carries quality and legal risk.
Rite Aid is preparing supervised consultations covering growth-hormone secretagogues. Join the waitlist to claim 20% off your first MK-677 order when consultations and ordering open.
Almost done
Confirm your email to secure 20% off your first compounded-peptide order. We'll notify you when consultations and ordering open.
Get 20% off your first compounded-peptide order
Join the early-access waitlist and we'll notify you the moment consultations and ordering open.
Blood work to track MK-677
MK-677 raises GH and IGF-1 and can raise blood sugar, so tracking covers both effectiveness and the specific safety risk:
- IGF-1 — the direct readout of the GH effect. It should rise if MK-677 is working.
- Comprehensive metabolic profile — fasting glucose, liver enzymes, and kidney function. The glucose number matters specifically here, because MK-677 can reduce insulin sensitivity.
Test before you start and again during use, watching glucose in particular.
Baseline tests before a peptide cycle
Check safety and response markers before starting. These tests help establish a baseline for liver, kidney, glucose, hormone, and recovery tracking.
Related peptides
MK-677 is most often stacked with or compared against the injectable growth-hormone peptides that act on the same GH axis: Ipamorelin and CJC-1295, the secretagogue and GHRH analog frequently run together, and Sermorelin, the established prescription GHRH analog.
For a broader GH-axis protocol, compare the options in peptides for muscle and performance.
FAQ
No. MK-677 (ibutamoren) is a non-peptide growth-hormone secretagogue — a small molecule, not a chain of amino acids. It's grouped with peptides because it acts on the same growth-hormone pathway, but it is chemically distinct, which is also why it isn't on the 2026 peptide reclassification list.
For body composition, recovery, and sleep, by raising growth hormone and IGF-1. It also increases appetite, which can be a benefit for gaining or a drawback for cutting.
Orally, typically once daily — no injection. That oral route is its main practical advantage over injectable GH peptides. It is a research chemical, not an FDA-approved product, so any use should be supervised by a provider.
Water retention, increased appetite, lethargy, and raised blood sugar. The blood-sugar effect is the most important to monitor, because MK-677 can reduce insulin sensitivity.
MK-677 is a research chemical, not FDA-approved. It is not on the April 2026 peptide reclassification list or the July 2026 advisory agenda, because those cover peptides and MK-677 is a non-peptide compound. "Research use only" products are not approved for human use.
IGF-1 is the readout — it should rise from baseline. Track it alongside fasting glucose, since the same GH elevation that signals effect can also raise blood sugar.